Afamitresgene Autoleucel
Brand names: Tecelra · Active ingredient: Afamitresgene Autoleucel
In short: TECELRA is indicated for the treatment of adults and pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as dete
What is Afamitresgene Autoleucel used for?
TECELRA is indicated for the treatment of adults and pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.
âš Boxed warning (FDA's strongest warning)
Cytokine Release Syndrome (CRS), which may be severe or life-threatening, occurred in patients receiving TECELRA. At the first sign of CRS, immediately evaluate patient for hospitalization and institute treatment with supportive care. Ensure that healthcare providers administering TECELRA have immediate access to medications and resuscitative equipment to manage CRS .
Afamitresgene Autoleucel dosage
For autologous use only. For intravenous use only.
The recommended dose is between 1.62 × 109 to 10 × 109 MAGE-A4 T cell receptor (TCR) positive T cells administered as a single intravenous infusion.
TECELRA is provided as a single dose for infusion in one or more infusion bag(s). Verify the number of bags received for the indicated dose prior to preparation for infusion.
Receipt of TECELRA
Plan for TECELRA to arrive prior to beginning lymphodepleting chemotherapy.
Ensure storage conditions in vapor phase of liquid nitrogen (≤ -130°C).
TECELRA is shipped directly to the healthcare facility in the vapor phase of a liquid nitrogen shipper. Upon receipt of TECELRA confirm the patient's identifiers on the metal cassette and product bag. Inspect the product for obvious signs of damage and contact 1-855-246-9232 if any anomalies are identified at the time of receipt.
Transfer TECELRA in the original packaging, containing the cassette(s) protecting the infusion bag(s), to onsite storage at ≤ -130°C before the shipper expires.
Store TECELRA in a manner that is consistent with How Supplied/Storage and Handling (16). If unforeseen circumstances prevent proper storage of TECELRA consistent with How Supplied/Storage and Handling (16), contact 1-855-246-9232 to arrange for return shipment.
Preparing Patient for TECELRA Administration
Pretreatment
Confirm availability of TECELRA at the healthcare facility prior to starting the lymphodepleting chemotherapy regimen.
Match the patient's identity with the patient identifiers on the TECELRA cassette(s) and infusion bag(s). Do not infuse TECELRA if the information on the patient-specific label(s) does not match the intended patient.
Administer a lymphodepleting chemotherapy regimen of fludarabine 30 mg/m2/day intravenously for 4 days starting on the seventh day before TECELRA infusion (Day-7 to Day -4) and cyclophosphamide 600 mg/m2/day intravenously for 3 days starting the seventh day before TECELRA infusion (Day -7 to Day -5).
Refer to fludarabine prescribing for information on fludarabine dosage in patients with renal impairment.
Short-acting or pegylated granulocyte-colony stimulating factor (G-CSF) may be administered at the discretion of the physician, and according with institutional standards, from 24 hours after last day of lymphodepleting chemotherapy (from Day -3) until resolution of neutropenia.
Premedication
Premedicate with an H1-antihistamine and acetaminophen according to institutional standard practice, approximately 30-60 minutes prior to TECELRA infusion.
Avoid prophylactic systemic corticosteroids, as it may interfere with the activity of TECELRA.
Preparation of TECELRA for Administration
Do not thaw the product until it is ready to be used. Coordinate the timing of TECELRA thaw and infusion. …
How to take Afamitresgene Autoleucel — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Discuss the following with the patient:
Inform patients that there is a chance of manufacturing or shipping failure (approximately 7% in the clinical trial). Therefore, a second manufacture of TECELRA may be attempted.
Inform patients that additional therapy (other than lymphodepletion) may be necessary before TECELRA manufacturing is completed. This may increase the risk of adverse reactions during the pre-infusion period, which could delay or prevent administration of TECELRA.
Inform patients that following infusion, it will be necessary to be monitored daily at the healthcare facility for at least 7 days for signs and symptoms of cytokine release syndrome (CRS). Patients must remain within proximity of a healthcare facility for at least 2 weeks following infusion.
Advise patients to seek immediate medical attention if any of the following occur:
Cytokine Release Syndrome: inform patients that symptoms may include fever, rigors, fast heartbeat, irregular heartbeat, low blood pressure, lightheadedness or dizziness, shortness of breath, nausea/vomiting, diarrhea, and headache . …
Warnings & precautions
Do not take this medicine if: DO NOT use TECELRA in patients who are heterozygous or homozygous for HLA-A*02:05P.
Cytokine release syndrome (CRS), including potentially life-threatening reaction has been observed following administration of TECELRA. CRS occurred in 72% of patients, including Grade ≥ 3 CRS in 2% patients. The median time to onset was 2 days (range: 1 to 7 days) and the median time to resolution was 3 days (range: 1 to 14 days). The most common symptoms were fever (97%), tachycardia (58%), hypotension (31%), nausea/vomiting (26%) and headache (21%) . Management for CRS (including Grade 1) was tocilizumab (40%) and siltuximab (1 patient). Eight participants also required corticosteroids for CRS management.
Ensure that healthcare providers administering TECELRA have immediate access to medications and resuscitative equipment to manage CRS. Ensure patients are euvolemic prior to initiating the infusions.
During and following TECELRA administration, closely monitor patients for signs and symptoms of CRS. Following treatment with TECELRA, monitor patients for at least 7 days at the healthcare facility for CRS. Continue to monitor patients for CRS for at least 2 weeks following treatment with TECELRA. Counsel patients to seek medical attention should signs or symptoms of CRS occur. At the first sign of CRS, immediately evaluate patient for hospitalization and institute treatment with supportive care based on severity and consider further management per current practice guidelines.
Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS) has been observed following administration of TECELRA. Six patients (4%) had ICANS; five Grade 1 and one Grade 2. Time to onset was 2 to 8 days and time to resolution was 1 to 7 days. Symptoms included mild mental status changes. …
Afamitresgene Autoleucel side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of TECELRA was evaluated in the SPEARHEAD-1 study (Cohorts 1, 2, 3) in which 137 patients with advanced synovial sarcoma received TECELRA across a dose of 1.01 × 109 to 10 × 109 MAGE-A4 TCR positive T cells .
Serious adverse reactions occurred in 35% of patients with synovial sarcoma. The most common serious adverse reactions (occurring in ≥ 5%) were CRS (7%) and infections (8%).
Table 1 summarizes adverse reactions that occurred in at least 10% of patients.
SOC Grouped Term | (N=137)
All Grades n (%) | Grade ≥ 3 n (%)
a Includes all adverse reactions reported following lymphodepleting chemotherapy and TECELRA, regardless of attribution to TECELRA
Gastrointestinal disorders
Nausea | 88 (64) | 5 (4)
Vomiting | 38 (28) | 2 (2)
Constipation | 40 (29) | 1 (1)
Diarrhea | 34 (25) | 0 (0)
Abdominal painIs a composite that includes multiple related terms. | 25 (18) | 5 (4)
General disorders and administration site conditions
Fatigue | 72 (53) | 2 (2)
Pyrexia | 41 (30) | 5 (4)
EdemaEdema includes ascites, fluid retention, hypervolemia, edema peripheral, pleural effusion, face edema, localized edema, peripheral swelling, and swelling. …
Drug interactions
None
About this medicine
TECELRA (afamitresgene autoleucel) is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy product consisting of CD4 and CD8 positive T cells transduced with a self-inactivating lentiviral vector (LV) expressing an affinity-enhanced T cell receptor (TCR) specific for the human MAGE-A4.
Autologous T cells transduced with MAGE-A4-c1032 LV express the affinity-enhanced TCR on the cell surface. The TCR recognizes an HLA-A*02 restricted MAGE-A4 peptide. MAGE-A4 is an intracellular cancer-testis antigen that has restricted expression in normal tissues and is expressed in synovial sarcoma.
TECELRA is prepared from the patient's peripheral blood mononuclear cells (PBMCs), which are obtained via a standard leukapheresis procedure. The PBMCs are enriched for T cells and are then transduced with a replication-incompetent LV containing the MAGE-A4 TCR transgene. The transduced T cells are expanded, washed, formulated into a suspension, and cryopreserved. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ab24631f-3364-46e1-8074-7244863bcbab. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate